---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-027273"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:29:47.942763+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# Lipocine presents LPCN 2101 posters at AES meeting; no specific data disclosed

## Summary
- Posters for LPCN 2101, a GABA A receptor PAM candidate for epilepsy, presented at AES Annual Meeting Dec 5-9, 2025.
- Poster 99.1 covers clinical PK and tolerability; Poster 99.2 covers oral toxicokinetics for women with epilepsy.
- No efficacy, safety, or numerical results included in the filing; exhibits referenced but not detailed.
- LPCN 2101 is a novel oral neuroactive steroid anti-seizure medication candidate.

## SEC filing metadata
- accession: 0001493152-25-027273
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315225027273/0001493152-25-027273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315225027273/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-027273
- JSON: https://secwatch.observer/filing/0001493152-25-027273.json
- Plain text: https://secwatch.observer/filing/0001493152-25-027273.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.